Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Targeting the Immunosuppressive Tumor Microenvironment for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–34.

    Article  Google Scholar 

  2. Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12:54.

    Article  Google Scholar 

  3. Lemke-Miltner CD, Blackwell SE, Yin C, et al. Antibody opsonization of a TLR9-agonist-containing virus-like particle enhances in situ immunization. J Immunol. 2020;204:1386–94.

    Article  CAS  Google Scholar 

  4. Miller AM, Lemke-Miltner CD, Blackwell SE, et al. Intraperitoneal CMP-001: a novel immunotherapy for treating peritoneal carcinomatosis of gastrointestinal and pancreaticobiliary cancer. Ann Surg Oncol. 2020. https://doi.org/10.1245/s10434-020-08591-7.

  5. Milhem M, Gonzales R, Medina T, et al. Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14–18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res. 2018;78(13 Suppl):Abstract nr CT144.

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, University of Iowa Hospitals and Clinics, University of Iowa, Iowa City, IA, USA

    Carlos H. F. Chan MD, PhD

  2. Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA

    Carlos H. F. Chan MD, PhD

Authors
  1. Carlos H. F. Chan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlos H. F. Chan MD, PhD.

Ethics declarations

Disclosures

The author has no conflicts of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chan, C.H.F. ASO Author Reflections: Targeting the Immunosuppressive Tumor Microenvironment for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer. Ann Surg Oncol 27 (Suppl 3), 759–760 (2020). https://doi.org/10.1245/s10434-020-08640-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-020-08640-1

Search

Navigation